Poolbeg Pharma PLC

POLB · LSE · Healthcare / Biotechnology

5.85GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close5.85

Open5.85

Day Range5.70 – 6.00

52-Week Range3.30 – 9.30

Volume98.34K

Market Cap54.81M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.01

Dividend Yield0.00%

Beta1.83

50-Day Avg8.12

200-Day Avg5.91

About

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Jeremy Skillington Ph.D.
Employees15
HeadquartersThe Clubhouse Holborn, London, United Kingdom, EC4A 3AG, UK
Websitehttps://www.poolbegpharma.com

Leadership

Mr. Cathal Martin FrielExecutive Chairman of The Board · b. 1964
Dr. Jeremy Skillington Ph.D.CEO & Director · b. 1971
Mr. Ian O'ConnellCFO & Director · b. 1987
Carol DaltonVice President of Investor Relations & Public Relations
Mr. Liam TremblePrincipal Scientist
Mr. Ross CrockettGroup Financial Controller

Financials

Income Statement

Currency: GBP	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0
Cost of Revenue	18.00K	26.00K	26.00K	114.00K	59.00K
Gross Profit	-18.00K	-26.00K	-26.00K	-114.00K	-59.00K
Operating Expense	2.36M	4.96M	5.01M	6.50M	6.36M
Operating Income	-2.38M	-4.99M	-5.04M	-6.62M	-6.42M
EBITDA	-2.32M	-4.75M	-4.66M	-6.00M	-6.36M
Net Income	-2.34M	-4.69M	-3.93M	-5.79M	-5.70M
R&D	414.00K	2.20M	1.68M	1.38M	1.52M
Interest Expense	0	-	-	-	-

Balance Sheet

Currency: GBP	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	23.02M	19.29M	15.43M	10.25M	9.94M
Total Liabilities	438.00K	966.00K	986.00K	974.00K	1.34M
Total Equity	22.58M	18.32M	14.44M	9.27M	8.60M
Cash	20.95M	16.19M	12.17M	7.82M	7.71M
Net Debt	-20.95M	-16.19M	-12.17M	-7.82M	-7.71M

Cash Flow

Currency: GBP	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-2.15M	-4.37M	-4.38M	-4.65M	-4.51M
Investing Cash Flow	-81.00K	-388.00K	359.00K	299.00K	-80.00K
Financing Cash Flow	23.18M	-	-	-	4.48M
Capital Expenditure	81.00K	597.00K	175.00K	129.00K	4.51M
Free Cash Flow	-2.23M	-4.96M	-4.02M	-4.78M	-4.84M
FCF to OCF	103.77%	113.67%	91.81%	102.78%	107.39%

Earnings

Report Date	Sep 6, 2022	Apr 12, 2023	May 27, 2025	Sep 29, 2025	Feb 26, 2026
EPS Estimate	0.00	0.00	0.00	0.00	0.00
EPS Actual	0.00	-0.01	-0.01	-0.00	0.00
Surprise	-	-	-	-	-
Timing	-	-	-	-	-

Key Statistics & Ratios

Market Cap54.81M

Enterprise Value61.38M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book8.03

EPS-0.01

Book Value0.012

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-5.97M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-58.55%

Return on Assets-38.73%

Shares Outstanding763.44M

Shares Float507.92M

Beta1.83

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%